Areas where scientific evidence is lacking or incomplete.
Cardiovascular safety and all-cause mortality data for long-term use of growth-hormone secretagogues (tesamorelin, ibutamoren) and newer multi-agonists (retatrutide) is largely absent. Approval trials capture 1–2 years of follow-up; real-world use is increasingly multi-year.
Implications: Clinicians prescribing these agents for insulin sensitivity or body-composition indications are extrapolating beyond the evidence base. Resolution: registry-scale 5–10 year prospective follow-up with cardiovascular and malignancy endpoints, particularly for tirzepatide and retatrutide.
The health consequences of sustaining pharmacological — rather than physiological — incretin levels over decades are unknown. Current outcome data covers years, not decades. The weight-regain-on-discontinuation pattern implies effectively lifelong exposure for most users who start.
Implications: The risk-benefit calculation for a 40-year-old starting tirzepatide assumes 30+ years of continuous exposure with no long-term data at that timescale. Resolution: cohort studies following current chronic users into multi-decade exposure; in the meantime, this is a known-unknown that should temper enthusiasm for early initiation.
How MOTS-c mRNA translocates from the mitochondria to the cytoplasm for translation, and how the resulting peptide enters target cells without being degraded while retaining biological activity, is not understood. The physical logistics of the molecule are a mechanistic blind spot.
Implications: Without understanding the transport pathway, dose-response prediction is unreliable and formulation strategies (oral vs SC vs IV) are empirical rather than principled. Resolution: basic research on the SLC25 transporter family and mitochondrial-to-cytosol peptide export mechanisms.
Weight-loss magnitude is the primary trial endpoint across the incretin class. The composition of that weight loss — specifically the lean-to-fat ratio and bone-density changes — is under-studied. Medically-induced rapid weight loss has been shown in other settings to drive clinically significant lean-mass and bone-density decline.
Implications: A patient losing 20% of body weight on tirzepatide with 30–40% of that being lean mass may end up functionally worse off despite the favourable biomarker numbers. Resolution: longitudinal DEXA studies paired with functional outcome measurement in diverse populations.
Retatrutide, tirzepatide, and newer multi-agonist trials enrolled adults. Paediatric and adolescent safety and efficacy data is largely absent despite rising rates of childhood and adolescent obesity and metabolic disease.
Implications: Off-label paediatric use is already happening in some jurisdictions without the evidence base to support it. Resolution: paediatric-specific RCTs with long-term growth and development endpoints; a regulatory and ethical challenge given this population's vulnerability.
Early data hints at ethnic differences in MOTS-c response to exercise, and clinical trial populations remain poorly diverse. Individual variability in response to incretin therapy is recognised clinically but not mechanistically decomposed.
Implications: Dose recommendations are currently one-size-fits-all at best, driven by mean population effect. Patients in under-represented populations are extrapolating from trial data that may not apply. Resolution: diverse-population RCTs and pharmacogenomic stratification of response.
Registered dietitians have highlighted severe gaps in patient-facing nutrition education for GLP-1 users — specifically protein-sufficiency, fibre management, and lean-mass preservation guidance. The practical implementation of these therapies lags the pharmacology.
Implications: A pharmacologically optimal therapy delivered into a nutritionally under-supported patient produces a degraded outcome. Resolution: structured nutrition-education programs paired with prescribing; currently only patchy.
The clinical case for pairing peptide therapy with specific nutritional co-factors (omega-3, zinc, chromium, specific antioxidants) is frequently made on mechanism. Direct clinical trial evidence testing these combinations head-to-head is largely absent.
Implications: Stack recommendations in this space are mechanism-driven, not outcome-driven. Some combinations will turn out to be meaningful; others will turn out to be placebo. Resolution: targeted factorial-design RCTs.
Exercise is known to stimulate endogenous MOTS-c production. The specific durations, intensities, and exercise modes that maximise endogenous mitokine secretion — and whether that endogenous induction rivals or exceeds exogenous dosing — is not characterised.
Implications: Patients might achieve meaningful insulin-sensitivity benefit through targeted exercise protocols alone, reducing the need for exogenous MOTS-c. Resolution: comparative studies of exercise prescriptions vs exogenous MOTS-c vs combination.
Comprehensive cost-effectiveness analyses comparing multi-year peptide therapy to bariatric surgery, endoscopic sleeve gastroplasty, or intensive lifestyle programs over horizons longer than five years are largely missing. Short-horizon analyses often favour peptides; long-horizon analyses may not.
Implications: Health systems making reimbursement decisions are operating with incomplete data. Resolution: 10-year cost-effectiveness modelling incorporating weight-regain-on-discontinuation and long-term adherence data.
Trial adherence is artificially high relative to real-world use. Real-world adherence data on these peptides — particularly after the first 12 months — is limited. GI side effects, cost, injection fatigue, and weight-loss plateau all plausibly degrade adherence.
Implications: Trial efficacy estimates overstate real-world effectiveness. Health systems and clinicians are extrapolating without the data. Resolution: pragmatic trials and registry data on persistence and adherence at 2, 5, and 10 years.
Much of the clinical literature on Khavinson bioregulators (including Pancragen for β-cell regeneration) is Russian-language and has not been independently replicated in Western Phase 3 trials. Mechanistically plausible, clinically unvalidated to current regulatory standards.
Implications: The bioregulator class is a genuinely interesting frontier that cannot yet be confidently recommended. Resolution: independent Phase 2/3 trials under Western regulatory oversight.
Expert disagreements and competing evidence.
Circulating MOTS-c levels are decreased in obese children and adolescents, consistent with the model that loss of mitochondrial signalling contributes to metabolic dysfunction.
Cohort studies in obese paediatric and adolescent populations. Negative correlation with BMI in adult male cohorts.
Source: Paediatric and adult MOTS-c cohort studies
Circulating MOTS-c concentrations were increased in the blood of obese mothers and their newborns compared with healthy controls — a direct contradiction of the "lower in obesity" finding.
Maternal and neonatal studies finding elevated MOTS-c in obese mothers and their newborns. Separate study showing positive correlation between liver fat and MOTS-c in non-diabetic adults.
Source: Maternal/neonatal cohort studies; liver-fat correlation research
Verdict Note
The two studies report opposite directions of effect in overlapping populations. Population differences (paediatric vs maternal/neonatal), assay differences, and small sample sizes may all contribute, but the raw disagreement is real.
Resolution
Do not use circulating MOTS-c as a clinical biomarker for metabolic status at this point. The assay and the biology are both too immature. Resolution requires larger, standardised cohort studies with consistent MOTS-c assays.
GIP receptor knockout mice are resistant to diet-induced obesity, suggesting that inhibiting GIPR prevents weight gain. Logically, a GIPR antagonist should be a weight-loss therapy.
GIPR knockout mice resistant to diet-induced obesity.
Source: Preclinical GIPR knockout studies
Chronically elevating GIP in transgenic mice reduces obesity, and pharmacological GIPR agonists produce dose-dependent weight reduction in humans. Logically, a GIPR agonist should be a weight-loss therapy — and tirzepatide proves this clinically.
Pharmacological GIPR agonism (tirzepatide) produces dose-dependent weight reduction in Phase 3 trials. Transgenic chronically-elevated GIP also reduces obesity in rodents.
Source: Tirzepatide Phase 3 trials; transgenic mouse studies
Verdict Note
Both directions can be correct at different doses and at different signalling levels. Physiological GIP activity appears to be pro-adipogenic at chronic low levels, while supraphysiological pharmacological activation appears to engage central nervous system pathways that drive weight loss. The dose-response curve is not monotonic.
Resolution
Clinically the debate is settled: tirzepatide (GIPR agonist) produces major weight loss and insulin-sensitivity improvement. The mechanism is not yet fully resolved. Next-generation drug design will need to distinguish physiological-level antagonism from supraphysiological agonism as therapeutic strategies.
Clinical analyses argue that GH secretagogues including tesamorelin improve insulin sensitivity specifically through reduction of visceral adipose tissue and improve overall body composition — framing effectively weight-loss-adjacent.
Clinical analyses of visceral adipose tissue reduction with tesamorelin.
Source: Clinical literature on GH secretagogues
FDA-approved prescribing information for EGRIFTA WR and EGRIFTA SV (tesamorelin) explicitly states the drug is "not indicated for weight loss management" and has a "weight neutral effect".
EGRIFTA WR and EGRIFTA SV prescribing information.
Source: FDA prescribing information
Verdict Note
The FDA label is unambiguous. The "weight loss adjacent" framing in some clinical literature stretches the indication beyond what regulators have approved. Tesamorelin reduces visceral adipose tissue specifically in HIV-associated lipodystrophy — the total-weight effect is small-to-neutral.
Resolution
Do not prescribe or use tesamorelin as a weight-loss drug. Its approved indication is HIV-associated visceral adiposity. Claims that it produces generalised weight loss are not supported by the regulatory evidence base. Body-composition shifts are real but modest and may not reflect on the scale.
GLP-1 receptor agonists improve metabolic health in part by increasing energy expenditure and stimulating hepatic fatty acid oxidation — suggesting a thermogenic component to their mechanism beyond appetite suppression.
Animal model studies showing BAT activation and increased hepatic fatty acid oxidation.
Source: Preclinical GLP-1 metabolism research
While GLP-1 appears to regulate brown adipose tissue and energy expenditure in animal models, there is "no convincing evidence that this occurs in humans". The weight-loss effect in humans is primarily mediated through appetite suppression.
Human studies have failed to reliably detect increased energy expenditure with GLP-1 therapy.
Source: Human metabolic studies of GLP-1 agonists
Verdict Note
The animal evidence for a thermogenic GLP-1 effect is real; the human evidence is weak to absent. Extrapolating from rodent BAT activation to human clinical mechanism is exactly the kind of translation step that often fails.
Resolution
The clinical weight-loss effect of GLP-1 agonists in humans should be attributed primarily to appetite suppression and reduced caloric intake, not increased energy expenditure. If a thermogenic component exists in humans, it is small enough that high-quality studies have not reliably detected it.
MOTS-c treatment restores mitochondrial respiration by increasing mitochondrial content, evidenced by higher citrate synthase activity — a classic marker of mitochondrial biogenesis.
Higher citrate synthase activity following MOTS-c treatment.
Source: Mitochondrial biogenesis marker studies
MOTS-c treatment caused a concentration-dependent decrease in the number of mitochondria per cell, potentially because it accelerated mitochondrial fusion and mitophagy — the opposite of net biogenesis.
Concentration-dependent reduction in mitochondria per cell, attributed to accelerated fusion and mitophagy.
Source: Direct mitochondrial counting studies
Verdict Note
Two mechanistic studies reach opposite conclusions about whether MOTS-c increases or decreases mitochondrial number. The citrate synthase finding and the direct-count finding cannot both be simple descriptions of the same biology — dynamics (fusion, fission, mitophagy) likely reconcile them, but the static "more or less" framing is genuinely unresolved.
Resolution
Do not claim MOTS-c "increases mitochondrial biogenesis" or "reduces mitochondrial number" without qualification. Mitochondrial dynamics — fusion, fission, mitophagy — are the level at which MOTS-c likely acts, and static counts may be misleading. Further research is needed on the dynamic picture.
A systematic review of BPC-157 literature through June 2024 explicitly states that "no clinical safety data were found" and that "in-human safety remains unknown". The one registered clinical trial has "unknown" status.
Systematic review through June 2024.
Source: 2024 systematic review
A 2025 review identifies three pilot studies that have examined BPC-157 in humans, reporting "no adverse effects" in these trials — including a 2025 pilot where intravenous BPC-157 was "well tolerated" in two healthy adults. An active Phase II trial (NCT04919239) for inflammatory bowel disease is ongoing with 240 participants.
2025 review identifying pilot studies and 2025 IV pilot. Active Phase II NCT04919239 with 240 participants for inflammatory bowel disease.
Source: 2025 review; ClinicalTrials.gov registration
Verdict Note
Both claims are technically correct — the reviews used different literature search dates and different definitions of "clinical data". The 2024 review was accurate at its search cutoff; the 2025 review captured newer pilot work and an active Phase II trial that post-dates the 2024 review. The underlying disagreement is about what counts as clinical data, not about what studies exist.
Resolution
As of 2026, BPC-157 has pilot-study level human safety data and one active Phase II trial — still below the threshold of "established human clinical profile" but above "no human data at all". Treat BPC-157 as an investigational compound with emerging human evidence, not as clinically validated and not as entirely untested in humans.